Halozyme Therapeutics (HALO Quick QuoteHALO - Free Report) reported $376.71 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 42.2%. EPS of $1.60 for the same period compares to $1.11 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $357.73 million, representing a surprise of +5.31%. The company delivered an EPS surprise of +3.73%, with the consensus EPS estimate being $1.54.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Royalties: $240.68 million versus the four-analyst average estimate of $244.19 million. The reported number represents a year-over-year change of +43.1%.
• Revenues- Revenues under collaboration agreements: $5.6 million compared to the $10.88 million average estimate based on four analysts. The reported number represents a change of -69.9% year over year.
• Revenues- Product sales, net: $130.42 million compared to the $102.82 million average estimate based on four analysts. The reported number represents a change of +67.1% year over year.

View all Key Company Metrics for Halozyme Therapeutics here>>>

Shares of Halozyme Therapeutics have returned -5.5% over the past month versus the Zacks S&P 500 composite's +9.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.